Career Guide · Path-iQ Global Pathology Review
Pathology residency is a 4-year postgraduate training programme (in the US/Canada) that prepares physicians to practise anatomic pathology (AP), clinical pathology (CP), or both (AP/CP). It is one of medicine's most intellectually diverse specialties — combining diagnostic microscopy, laboratory medicine, molecular diagnostics, and increasingly, AI-assisted image analysis — and continues to grow in demand as precision medicine creates new biomarker roles for pathologists at every cancer treatment decision.
| Country | Programme | Duration | Structure | Certifying Body |
|---|---|---|---|---|
| United States | AP/CP combined or AP-only or CP-only residency | 4 years (AP/CP); 3 years (AP-only or CP-only) | ACGME-accredited hospital programmes; match via NRMP; ABP written + oral board exams | American Board of Pathology (ABP) |
| Canada | Anatomical Pathology or General Pathology residency | 5 years (AP); 5 years (GP = AP + CP) | CAPER-accredited programmes; CaRMS match; RCPSC fellowship and Royal College exams | Royal College of Physicians and Surgeons of Canada (RCPSC) |
| United Kingdom | Histopathology specialty training (ST1–ST5) | 5 years ST1–5; 2-year subspecialty fellowship optional | Run-through training from ST1; FRCPath Part 1 (ST2–3) and Part 2 (ST5) exams; deanery-allocated posts | Royal College of Pathologists (RCPath) |
| Germany | Facharzt für Pathologie | 5 years Weiterbildung (postgraduate training) | Hospital-based training (Weiterbildungsstätte); Landesärztekammer examination; no national match | Landesärztekammer (state medical chambers) |
| France | DES Anatomo-Cyto-Pathologie | 5 years (internat) | ECN national examination determines specialty and region; hospital rotations; DESC for subspecialties | Collège des enseignants en Anatomie et Cytologie Pathologiques (CEAP) |
| Australia / New Zealand | Anatomical Pathology / General Pathology FRCPA | 5 years | College-accredited training posts; Written Examination (Part 1) and practical Part 2; clinical supervisor sign-off | Royal College of Pathologists of Australasia (RCPA) |
| India | MD Pathology | 3 years post-MBBS | University-based or hospital-based MD programme; MCI/NMC-recognised institutions; NEET-PG entrance; DNB as alternate | Medical Council of India / National Medical Commission (NMC); National Board of Examinations (DNB) |
Pathology is a moderately competitive specialty in the US NRMP Match. Unlike surgery or radiology, it does not require extremely high board scores to match, but research experience, strong letters of recommendation, and demonstrated interest in pathology (externships, laboratory research) are increasingly important. International medical graduates (IMGs) are welcomed — pathology has one of the higher IMG match rates among ACGME specialties.
| Metric | 2024 Match Data |
|---|---|
| Total positions offered (AP/CP, AP, CP) | ~650–680 positions (varies year to year; slight growth trend) |
| Overall fill rate | ~85–90% (pathology has historically had some unfilled positions; improving as specialty interest grows) |
| US MD seniors matching | ~70–75% of applicants match; USMLE Step 1 mean ~240 (pass/fail since 2022 limits discrimination) |
| IMG match rate | ~50–60% of IMG applicants match; among the more IMG-friendly surgical-adjacent specialties |
| Research publications (median) | 2–4 publications for matched applicants at academic programmes; 0–2 for community programmes |
| Away rotations | 1–2 away rotations strongly recommended for applicants targeting top 20 academic programmes |
| Most competitive programmes | Johns Hopkins, UCSF, MGH/Harvard, Mayo Clinic, Memorial Sloan Kettering, Stanford, Michigan, Columbia |
After completing a pathology residency, most pathologists in academic and large community settings pursue a 1-year (occasionally 2-year) fellowship in a subspecialty. Fellowship training has become effectively mandatory for academic pathology positions and is increasingly expected at large community cancer centres.
| Fellowship | Duration | Career Path | Demand Level 2026 |
|---|---|---|---|
| Surgical Pathology | 1 year | Academic medical centres; large community hospitals; subspecialty surgical pathology within an organ system | High — most common fellowship; broad applicability |
| Molecular Genetic Pathology (MGP) | 1 year | Academic medical centres; genomics laboratories; cancer centres; pharma/biotech pathology roles | Very high — fastest growing; critical for precision oncology pipeline |
| Haematopathology | 1 year | Academic; cancer centres; haematology-oncology programmes; flow cytometry-heavy practice | High — perennially in demand; strong subspecialty identity |
| Cytopathology | 1 year | Academic; radiology-affiliated practices; high-volume cytology centres; EBUS-FNA expertise valued | High — FNA/EBUS growth driving demand |
| Neuropathology | 2 years (ACGME) | Academic neuroscience centres; brain tumour programmes; epilepsy surgery centres | Moderate — small subspecialty; high demand per position; WHO CNS 2021 genomics created new complexity |
| Breast Pathology | 1 year | Breast programmes; comprehensive cancer centres; academic general surgical pathology | High — biomarker complexity and HER2-low driving new demand |
| Forensic Pathology | 1 year (ACGME) | Medical examiner / coroner offices; academic forensic programmes; military pathology | Moderate — chronic undersupply of forensic pathologists in US; steady government/ME demand |
| Dermatopathology | 1 year | Dermatopathology laboratories; academic dermatology-pathology programmes; often dual dermatology + pathology trained | High — cosmetically and oncologically driven volume growth; melanoma reclassification creates complexity |
| Transfusion Medicine / Blood Banking | 1 year | Blood centres; hospital blood banks; academic transfusion medicine programmes | Moderate — essential but small subspecialty |
| Computational / Digital Pathology | 1 year (informal; some ACGME-accredited programmes emerging) | AI-pathology companies; academic digital pathology programmes; clinical trials; pharma | Rapidly growing — most forward-looking fellowship for 2026–2030 |
The American Board of Pathology (ABP) offers primary certificates in Anatomic Pathology (AP), Clinical Pathology (CP), and combined AP/CP. After completing residency, candidates must pass a qualifying examination (written, computer-based) and a certifying examination (oral, held twice yearly). Primary certificate holders may then apply for subspecialty certificates (added qualifications) in: Neuropathology, Dermatopathology, Forensic Pathology, Molecular Genetic Pathology (joint with ABMGG), Cytopathology, Haematopathology, Chemical Pathology, Immunopathology, Medical Microbiology, and Blood Banking/Transfusion Medicine.
Maintenance of Certification (MOC): ABP-certified pathologists must complete MOC every 10 years, comprising continuing medical education (CME) credits, self-assessment modules (SAMs), and Practice Quality Improvement (PQI) activities. ABIM-model MOC participation through CAP, ASCP, or specialty societies satisfies most requirements.
| Domain | High-Yield Topics |
|---|---|
| Surgical pathology — GI | Barrett's oesophagus grading; gastric intestinal metaplasia and OLGA staging; colon polyp classification; Lynch syndrome MSI/MMR IHC; pancreatic cystic neoplasm classification (MCN vs IPMN vs SCN) |
| Surgical pathology — breast | Nottingham grading; ER/PR/HER2 ASCO/CAP criteria; DCIS vs ALH vs LCIS; phyllodes tumour grading; sentinel node staging (ITC vs micromet vs macromet) |
| Surgical pathology — gynaecological | Endometrial carcinoma molecular classification (POLE, MMR-d, p53-abnormal, NSMP); cervical cancer SCC vs adeno; FIGO staging integration; ovarian tumour classification |
| Haematopathology | WHO 2022 haematolymphoid classification; flow cytometry interpretation; DLBCL COO (Hans algorithm); CLL/SLL vs MCL (cyclin D1, SOX11, IGHV); MDS diagnostic criteria; MPN JAK2/CALR/MPL |
| Neuropathology | WHO 2021 CNS classification molecular integration; IDH1/2 mutation and IHC; MGMT methylation; glioblastoma hallmarks; medulloblastoma groups; IDH-mutant astrocytoma vs oligodendroglioma (1p/19q) |
| Clinical pathology — chemistry | Troponin kinetics in NSTEMI; HbA1c limitations; tumour marker interpretation (PSA, CA-125, CEA); blood gas interpretation; acute kidney injury vs CKD differentiation |
| Clinical pathology — microbiology | Gram stain and culture interpretation; antibiotic susceptibility (MIC); MRSA decolonisation; blood culture contamination vs true bacteraemia; fungal infection in immunocompromised |
| Molecular pathology | NGS platforms (amplicon vs hybrid capture); variant classification (ACMG 5-tier); fusion detection by RNA NGS; somatic vs germline distinction; MSI and TMB scoring |
Historically the most prestigious pathology residency in the US. Home of William Osler's era pathological training tradition. Exceptional surgical pathology, haematopathology, and molecular pathology volume. Produces disproportionately high share of academic pathology faculty.
Highest-volume cancer-focused pathology programme in the world. Unmatched exposure to rare tumours, intraoperative frozen sections, molecular diagnostic complexity, and clinical trial pathology. Ideal for trainees targeting oncological subspecialties.
Among the largest AP/CP combined pathology programmes in the US; exceptional CP training alongside surgical pathology. Strong fellowship pipeline into haematopathology, molecular pathology, and transfusion medicine. IHC consultation service receives international cases.
One of the UK's major histopathology training centres; large autopsy programme (increasingly rare), strong subspecialty rotations, and proximity to RCPath headquarters facilitating FRCPath exam preparation. Active digital pathology implementation programme.
Largest German university hospital and major pathology training centre. One of Europe's highest-volume autopsy services; comprehensive Weiterbildung across AP and molecular pathology. Strong research integration with the Berlin Institute of Health.
India's premier cancer centre; the MD Pathology programme at TMC offers exposure to the highest-volume cancer pathology in South Asia. Training encompasses the full range of surgical pathology, cytology, and immunohistochemistry with emerging molecular diagnostics capability.